Johnson & Johnson Newsroom

J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids

Zacks 21:00

Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies

Benzinga20:30

Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform -- Barrons.com

Barron's03:52

Investors Heavily Search Johnson & Johnson (JNJ): Here Is What You Need to Know

Zacks 01:40

Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Microsoft, Others

Seeking AlphaDec 2 22:55

Express News | J&J: Mentor Memorygel Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction

BreakingsDec 2 21:01

Express News | Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for Tremfya® (Guselkumab)

BreakingsDec 2 21:00

Express News | France has issued guidelines to support businesses in using ai.

BreakingsNov 30 11:05

Express News | The annual pharmaceutical imports value of Peking Tianzhu Comprehensive Bonded Zone is approximately 120 billion yuan.

BreakingsNov 29 22:12

Express News | Two innovative drugs from johnson & johnson have been included in the new national medical insurance catalog.

BreakingsNov 28 12:48

Investors in Johnson & Johnson (NYSE:JNJ) Have Seen Decent Returns of 30% Over the Past Five Years

Yahoo FinanceNov 26 22:00

Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?

Yahoo FinanceNov 26 16:17

J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC

Zacks Nov 25 21:35

Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share

November 24th (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on November 26th, 2024.Shareholders of record on November 26th, 2024 will receive 1.24 USD dividend per share on

Futu NewsNov 25 09:00

Johnson & Johnson (JNJ.US) has submitted a regulatory application to the FDA for its antibody therapy to treat moderate to severe active ulcerative colitis.

Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biological Product License Application (sBLA) to the FDA in the USA.

Zhitong FinanceNov 24 16:51

Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch

Yahoo FinanceNov 23 23:16

Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC

Seeking AlphaNov 23 10:25

Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program

Seeking AlphaNov 23 00:50

Express News | Johnson & Johnson is seeking approval from the FDA to use the subcutaneous induction therapy of TREMFYA (GUSELKUMAB) to treat ulcerative colitis.

BreakingsNov 23 00:38

Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis

MT NewswiresNov 22 21:47